We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Schwab International Equity ETF
SCHF
$65.6B
| $674K | ﹤0.01% |
37,838
-5,862
| -13% | -$104K |
|
427
Vanguard Mid-Cap ETF
VO
$106B
| $671K | ﹤0.01% |
12,192
-5,596
| -31% | -$293K |
|
428
Alibaba
BABA
$269B
| $662K | ﹤0.01% |
7,939
-45
| -0.6% | -$3.94K |
|
429
Robert Half
RHI
$3.61B
| $657K | ﹤0.01% |
8,732
-3,535
| -29% | -$252K |
|
430
Energy Transfer Partners
ET
$70.1B
| $653K | ﹤0.01% |
51,400
-1,600
| -3% | -$20.3K |
|
431
Prologis
PLD
$138B
| $653K | ﹤0.01% |
5,321
-349
| -6% | -$42.9K |
|
432
Schwab Emerging Markets Equity ETF
SCHE
$12.3B
| $652K | ﹤0.01% |
26,466
-3,100
| -10% | -$75.8K |
|
433
Hurco Companies Inc
HURC
$137M
| $651K | ﹤0.01% |
30,050
-500
| -2% | -$11.3K |
|
434
Vanguard Dividend Appreciation ETF
VIG
$111B
| $642K | ﹤0.01% |
3,950
-4,650
| -54% | -$728K |
|
435
Tootsie Roll Industries
TR
$2.82B
| $637K | ﹤0.01% |
19,668
-228
| -1% | -$8.32K |
|
|
MMP
436
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $629K | ﹤0.01% |
10,100
-26,217
| -72% | -$1.53M |
|
|
B
437
Barrick Mining
B
$62.2B
| $625K | ﹤0.01% |
36,900
-577
| -2% | -$10.5K |
|
438
RUM Group Inc
RUM
$1.57B
| $623K | ﹤0.01% |
69,797
| – | – |
|
|
FREE
439
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
| $617K | ﹤0.01% |
153,500
| – | – |
|
440
PIMCO 15+ Year US TIPS Index Exchange-Traded Fund
LTPZ
$694M
| $615K | ﹤0.01% |
10,245
-3,000
| -23% | -$181K |
|
441
Northrim BanCorp
NRIM
$603M
| $606K | ﹤0.01% |
61,596
| – | – |
|
442
Eastman Chemical
EMN
$7.8B
| $591K | ﹤0.01% |
7,062
-12,262
| -63% | -$997K |
|
443
Tanger
SKT
$4.82B
| $589K | ﹤0.01% |
26,675
| – | – |
|
444
Steris
STE
$20.9B
| $581K | ﹤0.01% |
2,584
| – | – |
|
445
Rayonier
RYN
$6.49B
| $577K | ﹤0.01% |
20,259
-937
| -4% | -$26.1K |
|
446
Tyler Technologies
TYL
$12.2B
| $577K | ﹤0.01% |
1,385
+180
| +15% | +$69.3K |
|
447
Safety Insurance
SAFT
$1.52B
| $575K | ﹤0.01% |
8,016
| – | – |
|
448
W.W. Grainger
GWW
$65.3B
| $572K | ﹤0.01% |
725
| – | – |
|
449
IDEX
IEX
$16.5B
| $571K | ﹤0.01% |
2,653
-1,825
| -41% | -$384K |
|
|
SGEN
450
DELISTED
Seagen Inc. Common Stock
SGEN
| $568K | ﹤0.01% |
2,950
-250
| -8% | -$49.7K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.